This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Clinical Updates in Chronic Myeloid Leukemia

Clinical Updates in Chronic Myeloid Leukemia

Format

Roundtable

Time to Complete

30 minutes

Released

April 1, 2019

Expires

April 1, 2020
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditsTM

Accredited Provider



Accredited by the University of Texas MD Anderson Cancer Center

Commercial Supporter

This activity is supported by an educational grant from Pfizer, Inc.

Program Description

Advance your understanding on how to better diagnose, treat, and monitor CML. Expert faculty from MD Anderson recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in CML. Highlighting key takeaways from this meeting series, faculty review the role of ABL tyrosine kinase inhibitor (TKI) agents in advancing treatment and delivering up-to-date care as well as discuss safety and tolerability of various approved TKIs in CML. They examine practical clinical strategies for managing potential toxicities resulting from treatment as well as optimizing health outcomes by personalizing treatment regimens based on patient-centered needs and disease characteristics.

This expert roundtable includes downloadable resources to improve care for your CML patients featuring key summary points and includes slides from the national visiting lecture series.

Goals

  • Acquired knowledge on evaluating patients’ health status and recognizing therapeutic options in regards to patient profiles. (Knowledge, Competence)
  • Enhanced knowledge of efficacy and tolerability, patient monitoring management, tied to available therapeutic regimes along with increased awareness of guideline recommendations. (Knowledge, Competence)
  • Clinicians will be informed of the different TKIs available for frontline treatment along with their unique toxicity profiles/drug-drug interactions leading to better patient monitoring and controlling adverse effects. (Knowledge, Competence, Performance)

Intended Audience

This is a targeted activity to increase physician awareness and the application of clinical evidence to develop personalized treatment strategies to optimize the care of patients with CML.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Review and discuss clinical considerations, including patient comorbidities, tolerability and safety profiles for frontline CML therapy options. (Knowledge, Competence)
  • Describe current guideline recommendations for disease monitoring response to therapy in CML and considerations for TKI discontinuation in appropriate patients. (Knowledge, Competence, Performance)
  • Understand strategies for managing treatment-related adverse events and drug-to-drug interactions associated with TKIs in patients with CML. (Knowledge)

Conflict Of Interest Disclosure Policy

The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.

The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713/792-5357.

The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Faculty

Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Daver* discloses the following:
Grant or research support: Bristol-Myers Squibb, Pfizer, Novartis, Servier Laboratories, NovaBay Pharmaceuticals, Daiichi Sankyo, Incyte
Honoraria: Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Servier Laboratories, Incyte

Michael Deininger, MD, PhD
M.M. Wintrobe Professor of Medicine
Chief of Hematology & Hematologic Malignancies
Department of Internal Medicine
University of Utah, Huntsman Cancer Institute
Salt Lake City, UT

Dr. Deininger discloses the following:
Grant or research support: Novartis, Pfizer
Paid consultant: Novartis, Pfizer
Membership on advisory committees: Blueprint, Novartis, Pfizer

Javier Pinilla-Ibarz, MD, PhD
Senior Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Dr. Pinilla‐Ibarz discloses the following:
Paid consultant: Novartis, Takeda, Pfizer
Speaker’s Bureau: Takeda

Elias J. Jabbour, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Jabbour* discloses the following:
Grant or research support: Amgen, Pfizer, Novartis, AbbVie, Bristol-Myers Squibb, Takeda

Michael J. Mauro, MD
Professor of Medicine
Leader, Myeloproliferative Neoplasms Program
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Mauro discloses the following:
Grant or research support: Novartis
Membership on advisory committees: Bristol-Myers Squibb, Novartis, Takeda, Pfizer

Jerald Radich, MD
Professor, University of Washington School of Medicine
Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Seattle Washington Cancer Center
Seattle, WA

Dr. Radich discloses the following:
Grant or research support: Novartis
Paid consultant: Novartis

STAFF DISCLOSURES

The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.

Planning Committee Members
Naval Daver, MD: see disclosure above
Elias J. Jabbour, MD: see disclosure above
Mansour Alfayez, MD
Michelle Forcier
Arman Nabatiyan
Greg Paladino

CME Activity Reviewers/Approvers
Diane C. Bodurka, MD, BS, MPH
Pei Lin, MD

The following CME Activity Reviewers/Approvers HAVE INDICATED FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity.

Issa Khouri, MD discloses the following:
Grant or research support: Pharmacyclics, Novartis
Paid consultant: TRM Oncology

Kenneth Rolston, MD discloses the following:
Grant or research support: Merck Inc., JMI Laboratories, Allergan
Membership on advisory committee or review panels, board membership, etc.: Allergan

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The University of Texas MD Anderson Cancer Center designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Instructions

Certificates awarding AMA PRA Category 1 CreditTM   or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.

Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.

Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue